Page last updated: 2024-08-23

escitalopram and Lung Injury, Acute

escitalopram has been researched along with Lung Injury, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Sun, S; Wang, T; Zheng, R	1

Other Studies

1 other study(ies) available for escitalopram and Lung Injury, Acute

Article	Year
Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade. Biochemical and biophysical research communications, 2022, 04-09, Volume: 599 Topics: Active Transport, Cell Nucleus; Acute Lung Injury; Animals; Drug Repositioning; Escitalopram; Histone Deacetylases; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Phosphorylation; Protein Serine-Threonine Kinases; RAW 264.7 Cells; Signal Transduction	2022

Article

Year

Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade.

Biochemical and biophysical research communications, 2022, 04-09, Volume: 599

Topics: Active Transport, Cell Nucleus; Acute Lung Injury; Animals; Drug Repositioning; Escitalopram; Histone Deacetylases; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Phosphorylation; Protein Serine-Threonine Kinases; RAW 264.7 Cells; Signal Transduction

2022